Making a World of Difference
Catalyst Pharmaceuticals’ mission is to improve the lives of those who suffer from rare diseases. Since our inception in 2002, we have operated with a steadfast commitment to our patients, people, and communities. Through innovative research and development practices, robust quality standards, and comprehensive safety procedures, we are able to follow through on our promise to provide patients with safe and effective drugs to improve the lives of those who suffer from rare diseases.
With a patient-centric focus embedded in everything we do, and a steadfast commitment to our patient community, we embarked on a comprehensive initiative to highlight the meaningful progress we are making as a sustainable Company with an ongoing commitment to continuous improvement.
ESG at Catalyst
At Catalyst, our guiding principle is to create long-term sustainable and collective value for all stakeholders. We made significant strides in 2022 in formalizing and advancing our ESG program, which is demonstrated by the release of our inaugural ESG Report and supported by the identification of material ESG topics. The inaugural report provides transparency across the Company’s sustainability practices and highlights our commitment to driving sustainable value across topics deemed most impactful to our business and for all our stakeholders.
Catalyst’s ESG Highlights:
ESG Program & Strategy
We are proud of our progress to build a well-rounded ESG program that is supported by comprehensive reporting. Our progress is demonstrated through:
• Our inaugural ESG Report, which aligns with leading 3rd-party frameworks including Sustainability Accounting Standards Board (“SASB”), Global Reporting Initiative (“GRI”), and United Nations Sustainable Development Goals (“UN SDGs”), and builds upon our 2021 SASB Disclosure;
• Engagement with key stakeholders to conduct our first formal materiality assessment and identifying most material ESG topics for the organization; and
• Tailored reporting to provide transparency in how Catalyst navigates key issues such as ensuring access to safe and affordable medicines and minimizing supply chain risks.
Environment
Although our environmental footprint is small given the nature of our industry and the size and structure of our business, we remain committed to:
• Reducing our impact across the organization and value chain; and
• Working towards evaluation of climate-related risks and opportunities that are relevant for our organization to manage their impact on our operations, supply chains, and stakeholders.
Social
• Provide patients with safe and effective drugs and ensuring all patients have access to Catalyst products regardless of their ability to pay;
• Offered several programs to optimize coverage and access, enabling patients without any other treatment options to receive the resources they need to take an active role in their healthcare to manage and improve their conditions; and
• Continued to subject all Catalyst products to extensive testing protocols to verify that each batch meets the appropriate standards for purity, potency, and quality prior to release for use.
Governance
• Maintain a formal ESG oversight structure driven by our Corporate Responsibility Steering Committee, and overseen by our Board and senior leadership, to continuously assess and improve our ESG program; and
• Ensure all of our employees follow the highest ethical standards throughout our Company in an effort to be transparent and effective in carrying out our duties to our stakeholders.
Our Impact:
- FIRDAPSE® has been used by over 1,000 unique patients since its launch
- Named as one of America’s Best Small Companies for 2023 by Forbes, ranking at 9 out of 100 from over 1,000 screened companies and building upon our positive impact as a ranked company in 2022.
- Named 2022 David J. Gury Company of the Year by BioFlorida, awarded for achieving significant milestones and contribution to the growth of Florida’s life sciences industry.
ESG Reports
Governance and Policies
Patient Resources
Contact Us
To provide feedback or submit questions regarding this report or Catalyst’s ESG initiatives, please contact [email protected]
Investor Contact
Mary Coleman
Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]
